Yazar "Uslu, S." için listeleme
-
Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis
Uslu, S.; Gülle, S.; Sen, G.; Capar, S.; Senel, S.; Dalkılıc, E.; Akar, S. (Multidisciplinary Digital Publishing Institute (MDPI), 2024)Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. ... -
LONG-TERM SURVIVAL OF THE FIRST BIOLOGIC TREATMENT IN PSORIATIC ARTHRITIS AND THE EFFECT OF THE SELECTED TREATMENT ON DRUG SURVIVAL; TURKBIO REGISTRY
Kocaer, S. B.; Inel, T. Yuce; Erez, Y.; Avsar, A. Koken; Uslu, S.; Karakas, A.; Onen, F. (Bmj Publishing Group, 2020)[No abstract available]
